• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Vapotherm Inc. (Amendment)

    2/16/24 10:50:33 AM ET
    $VAPO
    Medical/Dental Instruments
    Health Care
    Get the next $VAPO alert in real time by email
    SC 13G/A 1 vapo_13gv1.htm VAPO 13G

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1)*

     

     

    Vapotherm, Inc.
    (Name of Issuer)
     
    Common Stock, $0.001 par value
    (Title of Class of Securities)
     
    922107305
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)
    o Rule 13d-1(c)
    o Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 92210730513G/APage 1 of 9 Pages

     

     

     

     

    1.

     

    NAME OF REPORTING PERSONS

    Kent Lake Partners LP

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)     o

    (b)     o

     

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5.

     

    SOLE VOTING POWER

    0

     

     

    6.

     

    SHARED VOTING POWER

    499,619

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    499,619

     

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    499,619

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.1% (See Note 1)

     

     

    12.

     

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    PN

     

           

    (1)Based on 6,138,333 outstanding shares of common stock as of November 2, 2023 as represented in the Issuer's 10-Q filed with the Securities and Exchange Commission ("SEC") on November 8, 2023.

     

     

    CUSIP No. 92210730513G/APage 2 of 9 Pages

     

     

     

    1.

     

    NAME OF REPORTING PERSONS

    Kent Lake Capital LLC

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)     o

    (b)     o

     

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5.

     

    SOLE VOTING POWER

    0

     

     

    6.

     

    SHARED VOTING POWER

    499,619 (See Note 3)

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    499,619 (See Note 3)

     

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    499,619 (See Note 3)

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.1% (See Note 2)

     

     

    12.

     

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    IA, HC

     

           

    (2)See Note (1) Above.

     

    (3)Pursuant to Rule 13d-4 under the Securities Exchange Act of 1934, as amended, Kent Lake Capital LLC expressly disclaims beneficial ownership over any of the securities reported in this statement, and the filing of this statement shall not be construed as an admission that Kent Lake Capital LLC is the beneficial owner of any of the securities reported herein.

    CUSIP No. 92210730513G/APage 3 of 9 Pages

     

     

     

    1.

     

    NAME OF REPORTING PERSONS

    Benjamin Natter

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)     o

    (b)     o

     

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5.

     

    SOLE VOTING POWER

    0

     

     

    6.

     

    SHARED VOTING POWER

    499,619

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    499,619

     

     

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    499,619

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.1% (See Note 4)

     

     

    12.

     

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    IN, HC

     

           

    (4) See Note (1) Above.

     

    CUSIP No. 92210730513G/APage 4 of 9 Pages

     

    Item 1(a).Name of Issuer:

     

    Vapotherm, Inc. (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    100 Domain Drive

    Exeter, NH 03833

     

    Item 2(a).Name of Persons Filing:

     

    This statement is filed by the entities and persons listed below, who are collectively referred to herein as "Reporting Persons", with respect to the shares of Common Stock (as defined in Item 2(d) below) of the Company:

     

    (i)Kent Lake Partners LP

     

    (ii)Kent Lake Capital LLC

     

    (iii)Benjamin Natter

     

    Item 2(b).Address of Principal Business Office or, if none, Residence:

     

    (i)Kent Lake Partners LP

    c/o Kent Lake Capital LLC

    300 East 2nd Street, Suite 1510, #1033

    Reno, NV 89501

     

    (ii)Kent Lake Capital LLC

    300 East 2nd Street, Suite 1510, #1033

    Reno, NV 89501

     

    (iii)Benjamin Natter

    c/o Kent Lake Capital LLC

    300 East 2nd Street, Suite 1510, #1033

    Reno, NV 89501

     

    Item 2(c).Citizenship:

     

    (i)Kent Lake Partners LP – DE

     

    (ii)Kent Lake Capital LLC – DE

     

    (iii)Benjamin Natter – USA

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, $0.001 par value per share

     

    Item 2(e).CUSIP Number:

     

    922107305

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not Applicable.

     

    CUSIP No. 922107305 13G/A Page 5 of 9 Pages

     

     

     

    Item 4.Ownership

     

    (i)Kent Lake Partners LP

     

    (a)Amount beneficially owned: 499,619 (See Note 5)

     

    (b)Percent of class: 8.1% (See Note 6)

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to vote or to direct the vote: 0

     

    (ii)Shared power to vote or to direct the vote: 499,619 (see Note 5)

     

    (iii)Sole power to dispose or to direct the disposition of: 0

     

    (iv)Shared power to dispose or to direct the disposition of: 499,619 (See Note 5)

     

    (ii)Kent Lake Capital LLC

     

    (a)Amount beneficially owned: 499,619 (See Note 5)

     

    (b)Percent of class: 8.1% (See Note 6)

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to vote or to direct the vote: 0

     

    (ii)Shared power to vote or to direct the vote: 499,619 (see Note 5)

     

    (iii)Sole power to dispose or to direct the disposition of: 0

     

    (iv)Shared power to dispose or to direct the disposition of: 499,619 (See Note 5)

     

    (iii)Benjamin Natter

     

    (a)Amount beneficially owned: 499,619 (See Note 5)

     

    (b)Percent of class: 8.1% (See Note 6)

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to vote or to direct the vote: 0

     

    (ii)Shared power to vote or to direct the vote: 499,619 (See Note 5)

     

    (iii)Sole power to dispose or to direct the disposition of: 0

     

    (iv)Shared power to dispose or to direct the disposition of: 499,619 (See Note 5)

     

    CUSIP No. 922107305 13G/A Page 6 of 9 Pages

     

     

    Note 5:

     

    Kent Lake Capital LLC is an investment adviser that is registered under the Investment Advisers Act of 1940. Kent Lake Capital LLC may be deemed to be the beneficial owner of all shares of Common Stock held by Kent Lake Partners LP (the "Fund"). Mr. Benjamin Natter, as Managing Member of Kent Lake Capital LLC, with the power to exercise investment and voting discretion, may be deemed to be the beneficial owner of all shares of Common Stock held by the Fund. Pursuant to Rule 13d-4 under the Securities Exchange Act of 1934, as amended, Kent Lake Capital LLC and Mr. Natter expressly disclaim beneficial ownership over any of the securities reported in this statement, and the filing of this statement shall not be construed as an admission that Kent Lake Capital LLC or Mr. Natter are the beneficial owner of any of the securities reported herein.

     

    Note 6:

     

    Based on 6,138,333 outstanding shares of common stock as of November 2, 2023 as represented in the Issuer's 10-Q filed with the SEC on November 8, 2023.

     

    Item 5.Ownership of Five Percent or Less of a Class:

     

    Not Applicable.

      

    Item 6.Ownership of More Than Five Percent on Behalf of Another Person:

     

    See Note 5 above. The Fund has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock covered by this Statement.

      

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:

     

    See Note 5 above.

     

    Item 8.Identification and Classification of Members of the Group:

     

    Not Applicable.

      

    Item 9.Notice of Dissolution of Group:

     

    Not Applicable.

      

    CUSIP No. 922107305 13G/A Page 7 of 9 Pages

     

     

    Item 10.Certifications:

     

    Each of the Reporting Persons makes the following certification:

     

    By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

     

    Date: February 15, 2024

     

     

     

    KENT LAKE PARTNERS LP

    By: Kent Lake GP LLC, its General Partner

    By: /s/ Benjamin Natter

    Name: Benjamin Natter

    Title: Managing Member

     

     

    KENT LAKE CAPITAL LLC

    By: /s/ Benjamin Natter

    Name: Benjamin Natter

    Title: Managing Member

     

     

    BENJAMIN NATTER

    By: /s/ Benjamin Natter

     

     

    CUSIP No. 922107305 13G/A Page 8 of 9 Pages

     

     

    EXHIBIT A

     

    Joint Filing Agreement Pursuant to Rule 13d-1

     

    This agreement is made pursuant to Rule 13d-l(k)(1) under the Securities Exchange Act of 1934, as amended (the "Act") by and among the parties listed below, each referenced to herein as a "Joint Filer". The Joint Filers agree that a statement of beneficial ownership as required by Sections 13(g) or 13(d) of the Act and the rules thereunder may be filed on each of his, her or its behalf on Schedule 13G or Schedule 13D, as appropriate, and that said joint filing may thereafter be amended by further joint filings. The Joint Filers state that they each satisfy the requirements for making a joint filing under Rule 13d-1(k).

     

     

    Dated:  February 15, 2024
         

    KENT LAKE PARTNERS LP

    By: Kent Lake GP LLC, its General Partner

    By: /s/ Benjamin Natter

    Name: Benjamin Natter

    Title: Managing Member

     

     

    KENT LAKE CAPITAL LLC

    By: /s/ Benjamin Natter

    Name: Benjamin Natter

    Title: Managing Member

     

     

    BENJAMIN NATTER

    By: /s/ Benjamin Natter

     

     

     

     

    CUSIP No. 922107305 13G/A Page 9 of 9 Pages

    Get the next $VAPO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VAPO

    DatePrice TargetRatingAnalyst
    5/6/2022$12.00 → $5.00Buy → Hold
    Canaccord Genuity
    4/7/2022$23.00 → $8.00Overweight → Underweight
    Piper Sandler
    More analyst ratings

    $VAPO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vapotherm Announces Closing of Merger

      EXETER, N.H., Sept. 20, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), announced today that it has closed its merger with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC. On June 17, 2024, the Company announced that it had signed a definitive agreement and plan of merger with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC, a leading health care investment firm ("Perceptive"), and its Perceptive Discovery Fund. Concurrently with the entry into the definitive agreem

      9/20/24 10:33:00 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Vapotherm Reports Second Quarter 2024 Financial Results

      EXETER, N.H., Aug. 12, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), today announced second quarter 2024 financial results and related highlights. Second Quarter 2024 Financial Results and Related Highlights Net revenue for the second quarter of 2024 was $16.9 million, an increase of 5.3% as compared to the second quarter of 2023Disposables revenue increased by 13.9% as compared to the second quarter of 2023U.S. disposables revenue increased by 25.9% as compared to the second quarter of 2023Gross margin in the second quarter of 2024 was 49.

      8/12/24 5:15:00 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Vapotherm Enters Into Definitive Merger Agreement; Transaction Would Result In Company Going Private

      EXETER, N.H., June 17, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), announced today that it has signed a definitive merger agreement with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC, a leading health care investment firm ("Perceptive"), and its Perceptive Discovery Fund.  Concurrently with the entry into the definitive merger agreement, our existing lender, investment affiliates managed by SLR Capital Partners ("SLR") have agreed to convert approximately $81.0 million of term debt into preferred equity of the newly-formed entity, and Perceptive will invest $50.0 million of new preferred equity capital into the b

      6/17/24 6:55:00 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care

    $VAPO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Arnerich Anthony L. bought $117,337 worth of shares (37,750 units at $3.11), increasing direct ownership by 263% to 24,509 units (SEC Form 4) (Amendment)

      4/A - VAPOTHERM INC (0001253176) (Issuer)

      10/4/23 4:11:34 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care

    $VAPO
    Leadership Updates

    Live Leadership Updates

    See more
    • Perimeter Medical Imaging AI Strengthens Leadership Team with Appointment of Experienced MedTech Executive, Adam Hodges, as Vice President, Sales and Marketing

      TORONTO and DALLAS, Sept. 8, 2023 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) ("Perimeter" or the "Company") – a commercial-stage medical technology company – today announced the appointment of experienced medtech sales executive, Adam Hodges, as its Vice President, Sales and Marketing, effective immediately. Adrian Mendes, Perimeter's Chief Executive Officer stated, "I am excited to welcome Adam to the Perimeter team as our senior leader responsible for the strategy and execution of our sales-related goals. Adam's extensive medtech b

      9/8/23 8:30:00 AM ET
      $IART
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Eargo Announces Strategic Additions to Board of Directors Following Patient Square Capital Becoming New Majority Shareholder

      SAN JOSE, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. ("Eargo" or the "Company") (NASDAQ:EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced the appointments of several new directors following the closing of the Company's rights offering as previously announced on November 29, 2022. Patient Square Capital became the Company's majority owner upon closing of the rights offering and conversion of Patient Square's senior secured convertible notes per its investment in June 2022. As previously announced, following the completion of the rights offering, Patient Square has the right to nominate a number of directors t

      12/7/22 4:05:00 PM ET
      $EAR
      $ITGR
      $VAPO
      Medical Specialities
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Medical/Dental Instruments

    $VAPO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Vapotherm Inc.

      SC 13D/A - VAPOTHERM INC (0001253176) (Subject)

      9/24/24 7:04:57 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Vapotherm Inc.

      SC 13D/A - VAPOTHERM INC (0001253176) (Subject)

      9/20/24 10:32:59 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Vapotherm Inc.

      SC 13G - VAPOTHERM INC (0001253176) (Subject)

      7/18/24 7:24:17 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care

    $VAPO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Arnerich Anthony L. returned $344,305 worth of shares to the company (232,993 units at $1.48), closing all direct ownership in the company (SEC Form 4)

      4 - VAPOTHERM INC (0001253176) (Issuer)

      9/24/24 5:01:08 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • President and CEO Army Joseph returned $43,419 worth of shares to the company (452,698 units at $0.10), closing all direct ownership in the company (SEC Form 4)

      4 - VAPOTHERM INC (0001253176) (Issuer)

      9/24/24 4:43:19 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • SVP & Chief Financial Officer Landry John returned $51,982 worth of shares to the company (71,661 units at $0.73), closing all direct ownership in the company (SEC Form 4)

      4 - VAPOTHERM INC (0001253176) (Issuer)

      9/24/24 4:14:26 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care

    $VAPO
    SEC Filings

    See more
    • SEC Form 15-12G filed by Vapotherm Inc.

      15-12G - VAPOTHERM INC (0001253176) (Filer)

      9/25/24 11:32:00 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Vapotherm Inc.

      EFFECT - VAPOTHERM INC (0001253176) (Filer)

      9/25/24 12:15:03 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Vapotherm Inc.

      EFFECT - VAPOTHERM INC (0001253176) (Filer)

      9/25/24 12:15:04 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care

    $VAPO
    Financials

    Live finance-specific insights

    See more
    • Vapotherm To Report Second Quarter 2023 Financial Results

      Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the second quarter of 2023 after the close of trading on Tuesday, August 8, 2023. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to the conference call on your telephone, please dial +1 (888) 330-2391 for U.S. callers, or +1 (240) 789-2702 for international callers, approximately ten minutes prior to the start time and reference conference code 6585549. To listen to a live webcast, please visit the Investors section of the Vapotherm website at: http://investors

      7/25/23 4:30:00 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Vapotherm Reports First Quarter 2023 Financial Results

      Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced first quarter 2023 financial results. First Quarter 2023 Summary and Highlights Total revenue for the first quarter of 2023 was $17.7 million Capital revenue increased by 28% as compared to the fourth quarter of 2022 due to strong HVT 2.0 sales Disposables revenue decreased by 12% as compared to the fourth quarter of 2022 due to the timing of the US flu season Gross margin in the first quarter of 2023 was 35.0% Gross margin increased by 750 basis points over the fourth quarter of 2022 due to initial benefits from the transition of operations to Mexico For the first quarter of 2023, GAAP oper

      5/3/23 4:10:00 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Vapotherm To Report First Quarter 2023 Financial Results

      Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the first quarter of 2023 after the close of trading on Wednesday, May 3, 2023. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to the conference call on your telephone, please dial +1 (888) 330-2391 for U.S. callers, or +1 (240) 789-2702 for international callers, approximately ten minutes prior to the start time and reference conference code 6585549. To listen to a live webcast, please visit the Investors section of the Vapotherm website at: http://investors.v

      4/27/23 4:30:00 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care

    $VAPO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Vapotherm downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded Vapotherm from Buy to Hold and set a new price target of $5.00 from $12.00 previously

      5/6/22 7:28:09 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Vapotherm downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Vapotherm from Overweight to Underweight and set a new price target of $8.00 from $23.00 previously

      4/7/22 7:25:32 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Piper Sandler reiterated coverage on Vapotherm with a new price target

      Piper Sandler reiterated coverage of Vapotherm with a rating of Overweight and set a new price target of $36.00 from $39.00 previously

      2/25/21 7:36:13 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care